Navigation Links
Neuroscience Researcher Has Positive Message for International Alzheimer's Awareness Week, July 6 - 12: 'Even Though World Economy is Declining, Alzheimer's Research is Advancing'
Date:7/7/2009

MADISON, Wis., July 7 /PRNewswire/ -- In the midst of generally gloomy worldwide economic news and rising global tensions, an American neuroscience researcher has a message of hope: The answer for Alzheimer's disease and other degenerative diseases of the brain that cause memory loss may be much closer than we realize.

Mark Underwood, president of the Madison, Wisconsin-based biotech company, Quincy Bioscience (www.quincybioscience.com), says several recent studies have confirmed a suspected link between unregulated, excessive calcium levels within the neurons and the occurrence of Alzheimer's disease.

"Simply put, we now know that it is 'calcium overload' within the neurons that causes those neurons to stop functioning and brings about cognitive impairment and symptoms associated with Alzheimer's," says Underwood.

"Knowing this link allows us to postulate that an effective treatment for Alzheimer's could be as simple as devising a process to remove the excess calcium ions from calcium-overloaded neurons and thereby restore normal neuronal function."

Underwood says Quincy's own study confirmed that cognitive function could be improved by lowering neuronal calcium concentrations.

"We asked 83 healthy volunteers with self-described poor memory to consume a supplement (Prevagen(R), www.prevagen.com) containing a protein found in jellyfish that buffers calcium by binding to it," says Underwood.

"After 90 days, 63% of the volunteers reported less forgetfulness, 81% reported they required fewer reminders to complete daily tasks, and 74% reported improved ability to find the correct words in a conversation."

Underwood says a key difference between normal, healthy individuals and those with Alzheimer's disease is the rate at which healthy neurons become overloaded with calcium.

"Humans are born able to manufacture their own calcium-binding proteins but we gradually stop producing them at about age 40, and that's when our neurons start to weaken and we begin to experience mild memory loss," says Underwood. "Those with Alzheimer's apparently stop producing these proteins at a faster rate so their cognitive impairment occurs with greater velocity."

Underwood says he is confident that a drug for Alzheimer's can be developed incorporating the jellyfish calcium-binding protein.

"We have shown that normal adults can improve their memory, focus, and concentration by lowering their neuronal calcium," says Underwood. "We are very optimistic that the same compound can now be tested on Alzheimer's patients to assess their level of cognitive improvement."

ABOUT QUINCY BIOSCIENCE (www.quincybioscience.com)

Quincy Bioscience is a biotech company located in Madison, Wisconsin focused on the discovery, development and commercialization of novel medicines to treat age related memory loss and the diseases of aging. The company's therapeutic products focus on alleviating the consequences of impaired calcium homeostasis - the imbalance of calcium ions thought to be related to neurodegenerative diseases such as Alzheimer's and Parkinson's.

Web: www.quincybioscience.com


'/>"/>
SOURCE Quincy Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimers Disease
2. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
3. Neuronetrix Announces Preliminary Alzheimers Study Results at the Society for Neuroscience Conference
4. Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
5. Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS)
6. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
7. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
8. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
9. Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
10. Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
11. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and ... This is in conjunction with this morning,s announcement of ... Thrombosis and Nutritional Insufficiency businesses. Cardinal Health ... operations will be at the bottom of its previous ...
(Date:4/18/2017)... DALLAS , April 18, 2017 Viverae ... proud to announce the integration of IBM ® ... platform to deliver targeted communications for a personalized experience. ... meaningful actions on their health in real time. The ... that matter most to members, wherever they are in ...
(Date:4/18/2017)... DIEGO , April 18, 2017  Astute Medical, ... a case series to be presented at the 2017 ... which begins today and continues through April 22. Physicians ... IGFBP-7 , used to assess risk for acute kidney ... decompensated heart failure (ADHF). Elevated levels ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... RawTrition now brings you BioEnergy which is ... from SUPERFOODS! , RawTrition is taking nutrients to the next level! ... body recognizes its raw form (unlike the synthetically made options that are on the ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... breakthrough topical cream that’s the first in a new class of photodynamic cosmetics ... overall appearance of skin, visibly reduce outward signs of aging, and minimize the ...
(Date:4/25/2017)... ... 2017 , ... As President Trump challenges the status quo ... administration could impact the employee benefits industry. James Slotnick, AVP, Government Relations, for ... make it through Congress. His discussion will focus on the current state of ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... targets, they rely on contracted partners to help with process innovation in drug ... combined drug formulation experience along with state-of-the-art analytical equipment in support of their ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... addition of predictive analytics to its patient care management module. Using this new ... before a patient has been initiated on continuous positive airway pressure (CPAP), oral, ...
Breaking Medicine News(10 mins):